SEC Form 4 · accession 0001193125-26-384042
Definium Therapeutics, Inc. · DFTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Barrow
Officer — Chief Executive Officer · Director
Period of report
Sep 2, 2026
Accepted (ET)
Sep 4, 2026 · 9:30 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001813814
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1,F2 | Sep 2, 2026 | A | 40,000 | $0.00 | A | 1,513,663 | D | |
| Common SharesF4 | Sep 3, 2026 | S | 19,023 | $37.94 | D | 1,494,640 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The common shares represent the first tranche of performance share units granted effective February 3, 2026. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement.
- F2Amount includes 417 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan on August 17, 2026.
- F3Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested performance restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022
- F4The reported price is a weighted average sales price. These shares were sold in multiple transactions on September 3, 2026 at prices ranging from $37.46 to $38.94. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.